The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors
Open accessAbstract
In an effort to find new pharmacological modalities to overcome resistance to ATP-binding-site inhibitors of Bcr–Abl, we recently reported the discovery of GNF-2, a selective allosteric Bcr–Abl inhibitor. Here, using solution NMR, X-ray crystallography, mutagenesis and hydrogen exchange mass spectrometry, we show that GNF-2 binds to the myristate-binding site of Abl, leading to changes in the structural dynamics of the ATP-binding site. GNF-5, an analogue of GNF-2 with improved pharmacokinetic properties, when used in combination with the ATP-competitive inhibitors imatinib or nilotinib, suppressed the emergence of resistance mutations in vitro, displayed additive inhibitory activity in biochemical and cellular assays against T315I mutant human Bcr–Abl and displayed in vivo efficacy against this recalcitrant mutant in a murine bone-marrow transplantation model. These results show that therapeutically relevant inhibition of Bcr–Abl activity can be achieved with inhibitors that bind to the myristate-binding site and that combining allosteric and ATP-competitive inhibitors can overcome resistance to either agent alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although many therapeutic agents targeting protein kinases are competitors for the nucleotide binding site, there is a growing interest in developing inhibitors that bind at remote sites (i.e., Abl kinase), working through an allosteric mechanism of inhibition (63, 64).”
From Dynamically committed, uncommitted, and quenched states encoded in protein kinase A revealed by NMR spectroscopy (2011) · cites this paper as [64]
In the citing paper
“Although many therapeutic agents targeting protein kinases are competitors for the nucleotide binding site, there is a growing interest in developing inhibitors that bind at remote sites (i.e., Abl kinase), working through an allosteric mechanism of inhibition (63, 64).”
From Dynamically committed, uncommitted, and quenched states encoded in protein kinase A revealed by NMR spectroscopy (2011) · cites this paper as [64]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
A synthetic inhibitor of the mitogen-activated protein kinase cascade.
Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., & Saltiel, A. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7686 · Cited by 2,679
A mammalian protein targeted by G1-arresting rapamycin–receptor complex
Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053
Joensuu, H., Roberts, P. J., Sarlomo-Rikala, M., Andersson, L. C., Tervahartiala, P., Tuveson, D., Silberman, S. L., Capdeville, R., Dimitrijevic, S., Druker, B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441404 · Cited by 2,037
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,612
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492
Self-citationThree-dimensional structure of the tyrosine kinase c-Src
Xu, W., Harrison, S. C., & Eck, M. J. (1997) · Nature · doi:10.1038/385595a0 · Cited by 1,418
Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase
Nagar, B., Hantschel, O., Young, M. A., Scheffzek, K., Veach, D., Bornmann, W., Clarkson, B., Superti-Furga, G., & Kuriyan, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00194-6 · Cited by 879
Hydrogen exchange mass spectrometry for the analysis of protein dynamics
Wales, T. E., & Engen, J. R. (2006) · Mass Spectrometry Reviews · doi:10.1002/mas.20064 · Cited by 862
Self-citationBranford, S., Rudzki, Z., Walsh, S., Grigg, A., Arthur, C., Taylor, K., Herrmann, R., Lynch, K. P., & Hughes, T. P. (2002) · Blood · doi:10.1182/blood.v99.9.3472 · Cited by 649
Tokumitsu, H., Chijiwa, T., Hagiwara, M., Mizutani, A., Terasawa, M., & Hidaka, H. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)39565-1 · Cited by 623
Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL
Azam, M., Latek, R. R., & Daley, G. Q. (2003) · Cell · doi:10.1016/s0092-8674(03)00190-9 · Cited by 613
Self-citationBurke, J. R., Pattoli, M. A., Gregor, K. R., Brassil, P. J., MacMaster, J. F., McIntyre, K. W., Yang, X., Iotzova, V. S., Clarke, W., Strnad, J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209677200 · Cited by 550
A Myristoyl/Phosphotyrosine Switch Regulates c-Abl
Hantschel, O., Nagar, B., Guettler, S., Kretzschmar, J., Dorey, K., Kuriyan, J., & Superti-Furga, G. (2003) · Cell · doi:10.1016/s0092-8674(03)00191-0 · Cited by 480
BARNETT, S. F., DEFEO-JONES, D., FU, S., HANCOCK, P. J., HASKELL, K. M., JONES, R. E., KAHANA, J. A., KRAL, A. M., LEANDER, K., LEE, L. L., et al. (2005) · Biochemical Journal · doi:10.1042/bj20041140 · Cited by 396
Bradeen, H. A., Eide, C. A., O'Hare, T., Johnson, K. J., Willis, S. G., Lee, F. Y., Druker, B. J., & Deininger, M. W. (2006) · Blood · doi:10.1182/blood-2006-02-004580 · Cited by 393
Allosteric inhibitors of Bcr-abl–dependent cell proliferation
Adrián, F. J., Ding, Q., Sim, T., Velentza, A., Sloan, C., Liu, Y., Zhang, G., Hur, W., Ding, S., Manley, P., et al. (2006) · Nature Chemical Biology · doi:10.1038/nchembio760 · Cited by 381
Self-citationHigh-Speed and High-Resolution UPLC Separation at Zero Degrees Celsius
Wales, T. E., Fadgen, K. E., Gerhardt, G. C., & Engen, J. R. (2008) · Analytical Chemistry · doi:10.1021/ac8008862 · Cited by 352
Self-citationFlying under the radar: the new wave of BCR–ABL inhibitors
Quintás-Cardama, A., Kantarjian, H., & Cortes, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2324 · Cited by 305
Semi-automated data processing of hydrogen exchange mass spectra using HX-Express
Weis, D. D., Engen, J. R., & Kass, I. J. (2006) · Journal of the American Society for Mass Spectrometry · doi:10.1016/j.jasms.2006.07.025 · Cited by 258
Self-citationDI- AND TRIPHOSPHOPYRIDINE NUCLEOTIDE ISOCITRIC DEHYDROGENASES IN YEAST
Kornberg, A., & Pricer, W. E. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)56102-0 · Cited by 256
High yield bacterial expression of active c‐Abl and c‐Src tyrosine kinases
Seeliger, M. A., Young, M., Henderson, M. N., Pellicena, P., King, D. S., Falick, A. M., & Kuriyan, J. (2005) · Protein Science · doi:10.1110/ps.051750905 · Cited by 219
Vajpai, N., Strauss, A., Fendrich, G., Cowan-Jacob, S. W., Manley, P. W., Grzesiek, S., & Jahnke, W. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801337200 · Cited by 212
Self-citationPrediction of Resistance to Small Molecule FLT3 Inhibitors
Cools, J., Mentens, N., Furet, P., Fabbro, D., Clark, J. J., Griffin, J. D., Marynen, P., & Gilliland, D. G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2148 · Cited by 178
Blencke, S., Zech, B., Engkvist, O., Greff, Z., Őrfi, L., Horváth, Z., Kéri, G., Ullrich, A., & Daub, H. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.02.029 · Cited by 152
Ray, A., Cowan‐Jacob, S. W., Manley, P. W., Mestan, J., & Griffin, J. D. (2007) · Blood · doi:10.1182/blood-2006-01-015347 · Cited by 128
Self-citationAzam, M., Nardi, V., Shakespeare, W. C., Metcalf, C. A., Bohacek, R. S., Wang, Y., Sundaramoorthi, R., Piotr Sliz, A., Veach, D. R., Bornmann, W. G., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600001103 · Cited by 112
Self-citationvon Bubnoff, N. C. C., Veach, D. R., van der Kuip, H., Aulitzky, W. E., Sänger, J., Seipel, P., Bornmann, W. G., Peschel, C., CLARKSON, B., & Duyster, J. (2005) · Blood · doi:10.1182/blood-2004-06-2445 · Cited by 102
Protein NMR in biomedical research
Jahnke, W., & Widmer, H. M. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-3382-3 · Cited by 84
Self-citationConformational disturbance in Abl kinase upon mutation and deregulation
Iacob, R. E., Pene-Dumitrescu, T., Zhang, J., Gray, N. S., Smithgall, T. E., & Engen, J. R. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811912106 · Cited by 81
Self-citationOppi, C., Shore, S. K., & Reddy, E. P. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.23.8200 · Cited by 78
Development of thioquinazolinones, allosteric Chk1 kinase inhibitors
Converso, A., Hartingh, T. J., Garbaccio, R. M., Tasber, E. S., Rickert, K. W., Fraley, M. E., Yan, Y., Kreatsoulas, C., Stirdivant, S. M., Drakas, B. A., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.12.076 · Cited by 75
Choi, Y., Seeliger, M. A., Panjarian, S. B., Kim, H., Deng, X., Sim, T., Couch, B. A., Koleske, A. J., Smithgall, T. E., & Gray, N. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.026633 · Cited by 56
Self-citationLee, T., Potts, S. J., Kantarjian, H. M., Cortes, J. E., Giles, F. J., & Albitar, M. X. (2008) · Cancer · doi:10.1002/cncr.23355 · Cited by 51
(2002) · PubMed
Cited by
Tumour heterogeneity and resistance to cancer therapies
Dagogo-Jack, I., & Shaw, A. T. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.166 · Cited by 3,846
Borst, O., Walker, B., Münzer, P., Russo, A., Schmid, E., Faggio, C., Bigalke, B., Laufer, S., Gawaz, M., & Lang, F. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350110 · Cited by 1,860
Targeting MET in cancer: rationale and progress
Gherardi, E., Birchmeier, W., Birchmeier, C., & Woude, G. V. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3205 · Cited by 1,423
The promise and peril of chemical probes
Arrowsmith, C. H., Audia, J. E., Austin, C., Baell, J., Bennett, J., Blagg, J., Bountra, C., Brennan, P. E., Brown, P. J., Bunnage, M. E., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1867 · Cited by 839
Self-citationTrends in kinase drug discovery: targets, indications and inhibitor design
Attwood, M. M., Fabbro, D., Sokolov, A. V., Knapp, S., & Schiöth, H. B. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00252-y · Cited by 779
Metadata
- Authors
- Zhang, J., Adrián, F. J., Jahnke, W., Cowan-Jacob, S. W., Li, A. G., Iacob, R. E., Sim, T., Powers, J., Dierks, C., Sun, F., Guo, G.-R., Ding, Q., Okram, B., Choi, Y., Wojciechowski, A., Deng, X., Liu, G., Fendrich, G., Strauss, A., Vajpai, N., Grzesiek, S., Tuntland, T., Liu, Y., Bursulaya, B., Azam, M., Manley, P. W., Engen, J. R., Daley, G. Q., Warmuth, M., & Gray, N. S.
- Venue
- Nature
- Published
- 2010-01
- Volume
- 463
- Issue
- 7280
- Pages
- 501-506
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2164242115
- Cited by
- 597
- References
- 39
- FWCI
- 31.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.